Q1 2026 Pacira Biosciences Inc Earnings Call Transcript
Key Points
- Pacira BioSciences Inc (PCRX) reported strong first-quarter results, indicating that their 5x30 strategy is delivering intended business results.
- EXPAREL, the company's flagship product, continues to demonstrate renewed growth, supported by expanded coverage and enhanced intellectual property protection.
- ZILRETTA and iovera have shown significant sales growth, with ZILRETTA sales increasing by 15% and iovera sales by 21% year-over-year.
- The company is advancing an innovative clinical stage pipeline, with promising assets like PCRX-201 for knee osteoarthritis and PCRX-2002 for post-surgical pain.
- Pacira BioSciences Inc (PCRX) has strong partnerships with companies like Johnson & Johnson MedTech and LG Chem, which are expected to expand their commercial reach and drive revenue growth.
- First-quarter sales were impacted by winter storms, which disrupted shipping and triggered returns.
- The company's non-GAAP gross margin slightly decreased to 80% from 81% last year.
- There is uncertainty regarding the expiration of the No Pain Act in 2027, which could impact future reimbursement policies.
- R&D expenses increased due to advancing Phase 2 studies, which may continue to rise in the short term.
- SG&A expenses have been elevated over the past five quarters, and while expected to decrease in the second half of the year, the exact magnitude of the reduction is unclear.
Good day and thank you for standing by. Welcome to the Q1 2026 Pacira Biosciences, Inc., earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Susan Mesco, Head of Investor Relations. Please go ahead.
Thank you. Good afternoon, everyone. Welcome to today's conference call to discuss our first quarter 2026 financial results.
Joining me are Frank Lee, Chief Executive Officer; Brendan Teehan, Chief Commercial Officer; and Shawn Cross, Chief Financial Officer.
Kristen Williams, Chief Administrative Officer and Secretary; Tony Malloy, Chief Legal Officer, and Jonathan Slonin, Chief Medical Officer, are also here for today's question-and-answer session.
Before we begin, let me remind you that this call will include forward-looking statements subject to the Safe Harbor provisions of federal securities laws. Such statements represent our judgment
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
